title: [Prospective evaluation of mouth and eye dryness induced by antimuscarinic drugs used for neurogenic overactive bladder in 35 patients with multiple sclerosis].
abstract: BACKGROUND
  Mouth and eye dryness are frequently reported by patients with multiple sclerosis (MS) as side effects of antimuscarinic drugs used for neurogenic overactive bladder. We evaluated the impact of antimuscarinic drugs prescription on these symptoms.
  
  
  METHODS
  MS patients consulting for overactive bladder were included. Xerostomia were evaluated at baseline and thirty days after treatment by self-reporting questionnaires (Xerostomia Quality of Life [X-Qol] and Xerostomia Questionnaire [XQ]), by salivary flow rate and sugar test. Xerophtalmia were evaluated by a self-reporting questionnaire (Ocular Surface Disease Index [OSDI]) and Schirmer test. Iatrogenic anticholinergic impregnation was evaluated by the Anticholinergic Drug Scale.
  
  
  RESULTS
  From January to December 2014, 35 patients were included. Mean age was 50.1±10.2 years, mean EDSS=4.9. Mean anticholinergic impregnation was 0.6±1.0. Before treatment, none correlation was found between anticholinergic impregnation and other parameters. Twenty-two patients were evaluated after treatment. At baseline and thirty days after treatment, mean scores were respectively: 0.78±0.51 and 0.73±0.43 (P=0.67) for X-Qol, 9.22±11.8 and 7.03±11.4 (P=0.32) for XQ, 18.8±14.9 and 13.9±11.6 (P=0.06) for OSDI. Mean salivary flow rates were respectively 1.54±1.11 and 1.22±1.3 (P=0.53), positive sugar tests concerned respectively 68% and 55% of patients (P=0.53), and positive Schirmer test concerned 50% before and after treatment.
  
  
  CONCLUSIONS
  Eye and mouth dryness exist in our MS population, even before prescription of antimuscarinic treatment, and is not getting worse after prescription. Those symptoms should not be the reason to stop an efficient treatment, but should be the reason to find and treat their aetiology.
  
  
  METHODS
  4.
authors.affiliation: Service de neuro-urologie, hôpital Tenon, groupe de recherche clinique en neuro-urologie (GREEN), UPMC université Paris 06, Sorbonne universités, AP-HP, GRC 01, 4, rue de la Chine, 75020 Paris, France. Electronic address: laura.weglinski@aphp.fr.
authors.forename: L
authors.initials: L
authors.lastname: Weglinski
authors.affiliation: Service de neuro-urologie, hôpital Tenon, groupe de recherche clinique en neuro-urologie (GREEN), UPMC université Paris 06, Sorbonne universités, AP-HP, GRC 01, 4, rue de la Chine, 75020 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Manceau
authors.affiliation: Service de neuro-urologie, hôpital Tenon, groupe de recherche clinique en neuro-urologie (GREEN), UPMC université Paris 06, Sorbonne universités, AP-HP, GRC 01, 4, rue de la Chine, 75020 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Thomas-Pohl
authors.affiliation: Service de neuro-urologie, hôpital Tenon, groupe de recherche clinique en neuro-urologie (GREEN), UPMC université Paris 06, Sorbonne universités, AP-HP, GRC 01, 4, rue de la Chine, 75020 Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Le Breton
authors.affiliation: Service de neuro-urologie, hôpital Tenon, groupe de recherche clinique en neuro-urologie (GREEN), UPMC université Paris 06, Sorbonne universités, AP-HP, GRC 01, 4, rue de la Chine, 75020 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Amarenco
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011446:Prospective Studies; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology; D014985:Xerophthalmia / Q000209:etiology*; D014987:Xerostomia / Q000209:etiology*
chemical_list: D018727:Muscarinic Antagonists
keywords: Anticholinergic drugs; Drug-related side effect; Dry eye syndrome; Effets secondaires; Multiple sclerosis; Neurogenic urinary bladder; Sclérose en plaques; Sécheresse oculaire; Traitement anticholinergique; Vessie neurologique; Xerostomia; Xérostomie